Dan Chard'un ücretlendirmesi Medifast'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2025	n/a	n/a	US$4m
Mar 31 2025	n/a	n/a	-US$7m
Dec 31 2024	US$6m	US$1m	US$2m
Sep 30 2024	n/a	n/a	US$7m
Jun 30 2024	n/a	n/a	US$29m
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$7m	US$1m	US$99m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$133m
Mar 31 2023	n/a	n/a	US$142m
Dec 31 2022	US$6m	US$981k	US$144m
Sep 30 2022	n/a	n/a	US$151m
Jun 30 2022	n/a	n/a	US$157m
Mar 31 2022	n/a	n/a	US$165m
Dec 31 2021	US$7m	US$914k	US$164m
Sep 30 2021	n/a	n/a	US$158m
Jun 30 2021	n/a	n/a	US$150m
Mar 31 2021	n/a	n/a	US$125m
Dec 31 2020	US$6m	US$909k	US$103m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$76m
Mar 31 2020	n/a	n/a	US$76m
Dec 31 2019	US$5m	US$843k	US$78m
Sep 30 2019	n/a	n/a	US$74m
Jun 30 2019	n/a	n/a	US$72m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$2m	US$675k	US$56m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 5.61M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 611.00K ).

Tazminat ve Kazançlar: Dan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dan Chard (60 yo)

9yrs

Görev süresi

US$5,609,855

Tazminat

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Chard	Executive Chairman & CEO	9yrs	US$5.61m	1.61% $ 2.3m
James Maloney	Chief Financial Officer	5.3yrs	US$1.35m	0.11% $ 147.6k
Anthony Tyree	Chief Business Operations Officer	3.8yrs	US$1.07m	0.13% $ 182.2k
Jason Groves	Executive VP	13.9yrs	US$1.09m	0.14% $ 190.1k
Nicholas Johnson	Chief Field Operations Officer	6.7yrs	US$1.13m	0.11% $ 150.9k
Jonathan MacKenzie	VP of Finance & Chief Accounting Officer	4.1yrs	Veri yok	0.014% $ 19.9k
Steven Zenker	Vice President of Investor Relations	2.6yrs	Veri yok	Veri yok
Claudia Greninger	Chief Human Resources Officer	6yrs	Veri yok	Veri yok

5.6yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: MED 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Chard	Executive Chairman & CEO	9yrs	US$5.61m	1.61% $ 2.3m
Jeffrey Brown	Lead Independent Director	10.3yrs	US$250.36k	0.31% $ 432.6k
George Bray	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Hoer	Independent Director	7.3yrs	US$218.11k	0.15% $ 204.7k
Andrea Thomas	Independent Director	6.3yrs	US$223.11k	0.13% $ 175.6k
John Foreyt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ming Xian	Independent Director	7.3yrs	US$208.66k	Veri yok
Lawrence Cheskin	Chairman of Scientific Advisory Board	16.9yrs	Veri yok	Veri yok
Sylvia Rowe	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Scott Schlackman	Independent Director	10.3yrs	US$225.61k	0.14% $ 196.6k
John Hayes	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Messina	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

9.0yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MED 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/10/03 14:22
Gün Sonu Hisse Fiyatı	2025/10/03 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Medifast, Inc. 11 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Anand Vankawala	Avondale Partners
Kara Anderson	B. Riley Securities, Inc.
Scott Van Winkle	Canaccord Genuity

Medifast Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medifast, Inc., Annual General Meeting, Jun 18, 2025

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Lead Independent Director notifies of intention to sell stock

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Independent Director notifies of intention to sell stock

Recent updates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2025

Medifast, Inc. to Report Q2, 2025 Results on Aug 04, 2025

Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price

Medifast: Coach Surge Fuels Growth

Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target

Medifast, Inc., Annual General Meeting, Jun 18, 2025

First quarter 2025 earnings: EPS exceeds analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Second Quarter 2025

Medifast, Inc. to Report Q1, 2025 Results on Apr 28, 2025

Price target decreased by 9.1% to US$15.00

Consensus revenue estimates fall by 13%

Price target decreased by 8.7% to US$15.75

Full year 2024 earnings: EPS exceeds analyst expectations

Medifast, Inc. Provides Earnings Guidance for the First Quarter of 2025

Medifast, Inc. to Report Q4, 2024 Results on Feb 18, 2025

Medifast: Strong Balance Sheet, But I Lack Conviction In The Turnaround

An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued

Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND for GLP-1 Users & Those Looking for Help to Keep Weight Off

Investor sentiment deteriorates as stock falls 15%

Now 23% undervalued

Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry

Consensus EPS estimates upgraded to US$0.04 loss, revenue downgraded

GLP-1 Medication Surge And Stalling Coach Productivity Threaten Revenue Decline

Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Now 21% undervalued after recent price drop

Consensus EPS estimates upgraded to US$0.32 loss

Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Medifast Business Continues To Shrink, Stock Still Risky

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 15% to US$21.25

Medifast: Significant Undervaluation Even As Struggles Persist

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

Investor sentiment deteriorates as stock falls 25%

Consensus EPS estimates fall by 54%

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

First quarter 2024 earnings: EPS misses analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Medifast: Cheap Valuation, Uncertain Future

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Medifast Is Getting Attractive

Investor sentiment deteriorates as stock falls 17%

Consensus revenue estimates fall by 15%

New major risk - Revenue and earnings growth

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2023 earnings: EPS misses analyst expectations

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Price target decreased by 14% to US$62.50

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Investor sentiment deteriorates as stock falls 16%

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Consensus EPS estimates increase by 11%, revenue downgraded

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Now 21% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023